in entropy, t absolute temperature, K equilibrium constant, and r gas constant). therefore, enthalpically (large negative Δh) and entropically driven (large positive tΔs) compounds with similar affinity are indistinguishable if potency alone is determined. it has been suggested that enthalpically driven scaffolds/compounds are more suitable for further optimization than entropically driven ones (see, e.g., freire 4 and ruben et al. 5 ). altogether, this indicates that potency as a sole criterion is not sufficient to precisely evaluate the molecules synthesized during drug discovery activities. Binding kinetic and thermodynamic measurements bring new information on the tested molecules, opening up new dimensions expending the one-dimensional space traditionally used when relying only on potency. during the compound optimization process, this should allow molecules to be identified (even within libraries of closely related analogs) with distinct pharmacological properties that may modulate the target protein in different ways.
technically, measurement of the binding kinetic parameters and the thermodynamic properties of compounds has been very challenging. however, with the progress of surface plasmon resonance (spr) and related technologies, small libraries of low molecular weight compounds are being tested today with medium throughput to determine their binding kinetic parameters. if these technologies cannot be used, binding kinetic parameters can also be measured in some cases using enzymatic assays. By contrast, determining the thermodynamic properties of compounds remains cumbersome. isothermal calorimetry (itc) is the standard method. 6, 7 however, itc calls for large quantities of purified proteins despite the technical advancements reducing the consumption of material. protein production is therefore still something of a bottleneck, especially when many compounds have to be tested. this hampers the use of thermodynamics in drug discovery, unless a prescreening method could be found for selecting candidate compounds to be tested in itc. we evaluate here the use of a fluorescence-based thermal shift assay (ftsa) as such a prescreening method.
the principle of ftsa involves the progressive heat denaturation of a protein in the presence of a fluorescent dye that only fluoresces upon binding to denatured proteins. [8] [9] [10] [11] the progressive denaturation of the protein therefore induces a progressive increase in fluorescence, allowing the determination of the protein melting temperature, t m , which corresponds to the temperature at which 50% of the protein is denatured. Because ftsa measurements are made in microplates using a standard pcr machine equipped with a charge-coupled device (ccd) camera, many data points can be recorded in short time frames. the binding of a ligand to a protein leads to the formation of a complex protein-ligand that usually exhibits a higher melting temperature, t m b , than the free protein. experiments have shown a good correlation between ligand potency measured in biochemical assays and shift in melting temperatures (Δt m = t m b -t m ) estimated in ftsa, [12] [13] [14] [15] and ftsa is already routinely used to triage hits identified from high-throughput screening (hts) campaigns. moreover, Δt m s obtained from ftsa are directly connected to the thermodynamic parameters of the ligand-protein interaction, 7, 16, 17 providing a link to the thermodynamic signatures of the compounds. altogether, this suggests that ftsa could be suitable as a prescreening method of selecting compounds for itc measurements. to evaluate this hypothesis, we have used as a model the type i insulin-like growth factor receptor (iGf1r) protein, which is an active drug discovery target for oncology, 18 and we have combined enzymatic assays, itc, and ftsa to determine whether ftsa can be used to identify compounds with different thermodynamic signatures from a library of analogs with closely related structures.
mAterIALS And metHodS

Protein production and compound analytics
the nonphosphorylated iGf1r protein has been produced and its purity assessed as previously described. 19 the compound stock solutions have been made from fresh powder at a concentration of 10 mm in dmso. the purity of the compounds was controlled by liquid chromatography/mass spectrometry (lc/ms), and their solubility in assay buffer was verified by dynamic light scattering 20 at concentrations up to 50 µm.
Enzymatic assays, ITC, and FTSA
the potency (ic 50 ) of the compounds determined in a radiometric assay with nonphosphorylated iGf1r and the itc measurements was carried out as previously described. 21 Because of the large amounts of protein required for itc measurements, the thermodynamic properties of a limited number of randomly chosen inhibitors were measured. for ftsa measurements, dmso solutions of compounds (1.3 µl-concentrations varying from 5 to 50 µm) were added to iGf1r (42 µl-final concentration 1 µm) diluted in hepes 50 mm (ph 7.4) and dithiothreitol (dtt) 1 mm and incubated at room temperature for 30 min prior to addition of 5× sypro orange fluorescent dye (7 µl; sigma 5692, sigma, st. louis, mo). thermal shift assays were run in 96-well pcr plates (mlp9651; Bio-rad, hercules, ca) sealed with optical-Quality sealing tape (msB1001; Bio-rad). the plates were heated in an icycler iQ real time pcr detection system (Bio-rad) from 25°c to 80°c in increments of 0.5°c. fluorescence changes were monitored with a ccd camera. the wavelengths of excitation and emission were 485 and 530 nm, respectively. the compounds, at their highest assay concentration, did not induce the fluorescence of sypro orange. the fluorescence imaging data were fitted with y = Bottom + (top -Bottom)/ (1 + 10^((t m -X) · hill slope)) to determine t m , which is the midpoint of the curve. y is the fluorescence intensity at temperature X, and Bottom and top are pretransitional and posttransitional fluorescence intensities, respectively. data points after the fluorescence intensity maximum were excluded from fitting. for each compound concentration, shifts in melting temperature were calculated using the equation Δt m = t m b -t m , where t m b is the melting temperature of iGf1r bound to a compound, and t m = 46.7 ± 0.1 °c (n = 25) is the melting temperature of free iGf1r. the Δt m max , the maximum shift in melting temperature induced by compound binding, was obtained using the equation corresponding to one-site binding (Graphpad prism version 4.02; Graphpad, la Jolla, ca): y = (Δt m max · X)/ (K + X), where y is the measured Δt m at the compound concentration X, and K is the ligand concentration that gives a thermal shift corresponding to Δt m max /2. curve fitting was carried out with Graphpad prism version 4.02.
reSuLtS And dIScuSSIon
the purity of the recombinant iGf1r protein used in the different assays was above 90% and the absence of phosphorylation confirmed by mass spectrometry as previously reported. 19 the purity of the compounds, verified by lc/ms, was higher than 95% (data not shown). their solubility was determined by dynamic light scattering, and the compounds were used in the assays at concentrations where they did not show any sign of aggregation. the chemical structure of the compounds used in this study cannot be disclosed for patent reasons. however, a precise knowledge of the structure of the individual compounds is not required because the scope of this study is not to establish a structure-activity relationship but to show that ftsa can help to identify compounds with different thermodynamic profiles in a library of closely related analogs. all the molecules tested in this study derive from the same common scaffold, which can only be substituted at three positions: a, B, and c. substitutions at position a are polar groups of different sizes. substitutions at position B are either small aliphatic groups (table 1, compounds 13, 14, 15, 17, and 18) or small polar groups (table 1, compounds 16 and 19) . substitutions at position c are large bulky aromatic groups. in the following, the groups of compounds a, B, or c correspond to sets of molecules with different substitutions at position a, B, or c, respectively. table 1 summarizes the results of the different measurements made in the course of this study. the potency of the compounds measured in the enzymatic assay varies from 6 to 3900 nm, showing that inhibitors with a broad range of activity (~3 orders of magnitude) were included in this analysis. these compounds are noncovalent adenosine triphosphate (atp) competitive inhibitors (data not shown). the melting temperature of the protein in the presence of the different compounds was determined by ftsa. Because t m usually increases with ligand concentration, 22 Δt m was measured at different compound concentrations. the data obtained from these experiments were fitted, as described in materials and methods, to determine Δt max , which is the maximum shift in melting temperature obtained with a compound (Fig. 1A) . three compounds (11, 12 , and 19; table 1) gave a negative Δt max , suggesting an interaction with unfolded iGf1r. 23 these three molecules, which are among the less potent inhibitors studied, were not further analyzed. a graphic plot of -log 10 (ic 50 ) versus Δt max for the remaining compounds reveals a good correlation between ic 50 and Δt max within each group of compounds (table 1 and lines in Fig. 1B) : the lower the ic 50 , the larger the Δt max . this is in agreement with published work showing that good relationships could be established between compound potency and data obtained from ftsa measurements (see, e.g., Bobkova et al., 12 lo et al., 9 matulis et al., 13 and mcdonnell et al. 14 ) . the combined analysis of -log 10 (ic 50 ) versus Δt max also reveals that two distinct populations of compounds exist among this set of molecules with closely related structures (ovals in Fig.  1B) . compounds from group a (also see below for group c compounds) form a first population, whereas inhibitors of group B belong to a second population. this observation would not have been possible using potency data alone.
to determine whether this difference is linked to the thermodynamic properties of the compounds constituting these two populations, itc experiments were carried out with several of them (table 1 ). all the inhibitors tested have a stoichiometry of 1 (data not shown). Group a compounds 1, 4, 7, 8, and 9 are largely enthalpy driven. Group B inhibitors 13, 14, 15, and 16 were also studied in itc. the results of these experiments indicate that 13, 14, and 15 have a distinct thermodynamic profile versus group a and c inhibitors. for these molecules, the enthalpic contribution to binding energy is strongly reduced, and for 13 and 15, entropy even becomes its largest component. compound 16 has a different thermodynamic profile (and a higher Δt m max than expected from its potency) because its enthalpic contribution to binding energy, although being smaller than for group a and c compounds, is larger than for other group B compounds. compound 16 might be different from all other group B compounds because it is the only one to possess a polar group at position B.
to determine whether the different thermodynamic behavior of group B compounds is linked to the presence of substitutions at position B, control experiments were also realized with compounds substituted at position c (group c compounds). data presented in Figure 1B and table 1 (compounds 23 and 24) show that these molecules have a similar behavior to group a compounds. these experiments reinforce the findings that only modifications at position B induce a different thermodynamic profile. this suggests that ftsa may help distinguish compound populations with different thermodynamic signatures as it is the case here with group B compounds. on the basis of these results, we propose that ftsa in combination with potency measurements could be used as a prescreening method to select compounds for calorimetry measurements. Because ftsa is fast, does not need sophisticated material/operations, and does not call for complex data analysis, it can easily be integrated into medicinal chemistry programs to identify compounds that should be further tested in itc. our analysis was conducted with a single protein target and one compound class. this therefore begs the question of whether a combined analysis of potency versus thermal stability would lead to similar results with other protein targets and different compounds. to our knowledge, no study has reported a combined analysis of potency versus thermal stability together with itc measurements that identify compound populations of the same scaffold with distinct thermodynamic profiles. however, several communications describe combined analyses of potency versus thermal stability. 12, 14, 15 Very interestingly, in their study on the fatty acid amide hydrolase, slaymaker et al. 15 were able to identify two different compound populations once they plotted a graph lnK i versus t m . unfortunately, no thermodynamic measurements were realized with these compounds. this nevertheless shows that it is possible to identify distinct compound populations in a combined analysis of potency versus thermal stability with a different protein and another type of ligand. we hope that reports describing such studies together with itc measurements will be published in the future to further validate the new approach presented here. it should be kept in mind that because ligands with very different physicochemical properties are difficult to compare, 7 this type of analysis should be carried out with series of compounds with closely related structures. inhibitors may interact with enzyme/substrate or enzyme/product complexes and not with the free enzyme as presented here. in these cases, it might be difficult (if at all possible) to use the method described here. ftsa is also difficult to use when compound series induce weak thermal stabilization of the target protein (small Δ t m max ). it has been recently proposed that combining kinetic information (more precisely, k off ) with potency data permits molecules with better pharmacological properties to be identified. 1-3 thermodynamics is rarely used in drug discovery because itc is still a very demanding procedure. however, thermodynamic parameters can also be very useful to select the most appropriate scaffolds. 4, 5 we believe that if the three biochemical factors of potency, kinetic, and thermodynamic parameters are combined in drug discovery, medicinal chemists exploring this three-dimensional space will be able to identify compounds that better modulate their target protein. using ftsa as described in this report may help researchers make use of the thermodynamic dimension more frequently in the future than is the case today. . the curves were fitted as described in materials and methods to determine t m and t m b and to calculate Δ t m = t m b -t m . the Δ t m measured at different compound concentrations (main graph) was then fitted as described in materials and methods to determine Δ t m max , which is the maximum shift in melting temperature induced by compound binding. (B) combined analysis of potency versus thermal shift. ic 50 s and Δt max are given in table 1. for better clarity, standard errors are not indicated (see table 1 ). Group a, B, or c compounds (compounds with different substitutions at positions a, B, or c) are represented by circles, squares, and triangles, respectively. compounds for which isothermal calorimetry measurements have been made are represented by closed circles, squares, and triangles. the linear relationships between ic 50 and Δt max are represented by lines. Group a and B, R 2 = 0.89; Group c, R 2 = 0.84. the dotted (groups a and c) and solid (group B) line ovals indicate the two populations of inhibitors.
